skip to main content
Idioma:

Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs

Muguruza, Carolina ; Meana, J Javier ; Callado, Luis F

Frontiers in pharmacology, 2016-05, Vol.7, p.130-130 [Periódico revisado por pares]

Switzerland: Frontiers Research Foundation

Texto completo disponível

Citações Citado por
  • Título:
    Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Drugs
  • Autor: Muguruza, Carolina ; Meana, J Javier ; Callado, Luis F
  • Assuntos: antipsychotic ; Antipsychotic drugs ; Drug therapy ; Glutamate ; human brain ; mGlu2R receptors ; Pharmacology ; Schizophrenia
  • É parte de: Frontiers in pharmacology, 2016-05, Vol.7, p.130-130
  • Notas: ObjectType-Article-2
    SourceType-Scholarly Journals-1
    ObjectType-Feature-3
    content type line 23
    ObjectType-Review-1
    Edited by: Francisco Ciruela, Universitat de Barcelona, Spain
    This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
    Reviewed by: Sâmia R. L. Joca, University of Sao Paulo, Brazil; Marián Castro, University of Santiago de Compostela, Spain
  • Descrição: Schizophrenia is a chronic psychiatric disorder which substantially impairs patients' quality of life. Despite the extensive research in this field, the pathophysiology and etiology of schizophrenia remain unknown. Different neurotransmitter systems and functional networks have been found to be affected in the brain of patients with schizophrenia. In this context, postmortem brain studies as well as genetic assays have suggested alterations in Group II metabotropic glutamate receptors (mGluRs) in schizophrenia. Despite many years of drug research, several needs in the treatment of schizophrenia have not been addressed sufficiently. In fact, only 5-10% of patients with schizophrenia successfully achieve a full recovery after treatment. In recent years mGluRs have turned up as novel targets for the design of new antipsychotic medications for schizophrenia. Concretely, Group II mGluRs are of particular interest due to their regulatory role in neurotransmission modulating glutamatergic activity in brain synapses. Preclinical studies have demonstrated that orthosteric Group II mGluR agonists exhibit antipsychotic-like properties in animal models of schizophrenia. However, when these compounds have been tested in human clinical studies with schizophrenic patients results have been inconclusive. Nevertheless, it has been recently suggested that this apparent lack of efficacy in schizophrenic patients may be related to previous exposure to atypical antipsychotics. Moreover, the role of the functional heterocomplex formed by 5-HT2A and mGlu2 receptors in the clinical response to Group II mGluR agonists is currently under study.
  • Editor: Switzerland: Frontiers Research Foundation
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.